Drugs / F-18-Fluorocholine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04102553 | Mar 2019 → Oct 2020 | prostate cancer | ABX advanced biochemical compounds GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F-18-Fluorocholine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04102553 ↗ |
| Modality | Diagnostic / imaging agent | “This study evaluates the diagnostic performance and safety of F-18-PSMA-1007 and F-18-Fluorocholine PET/CT imaging” NCT04102553 ↗ |